share_log

Recursion Pharmaceuticals | 8-K: Current report

Recursion Pharmaceuticals | 8-K: Current report

Recursion Pharmaceuticals | 8-K:重大事件
美股SEC公告 ·  06/07 09:01

Moomoo AI 已提取核心信息

Recursion Pharmaceuticals, Inc. conducted its 2024 annual meeting of stockholders on June 3, 2024. During the meeting, two Class III directors were elected to serve until the 2027 annual meeting. The elected directors are Blake Borgeson, Ph.D., with 165,914,956 votes for and 26,093,759 withheld, and Dean Y. Li, M.D., Ph.D., with 166,211,058 votes for and 25,797,657 withheld. Additionally, an advisory resolution to approve executive compensation was passed with 188,317,831 votes for, 2,887,180 against, and 803,704 abstentions. The details of these proposals and their descriptions were previously filed with the SEC in the definitive Proxy Statement on April 23, 2024. The annual meeting's outcomes were reported in compliance with the SEC regulations.
Recursion Pharmaceuticals, Inc. conducted its 2024 annual meeting of stockholders on June 3, 2024. During the meeting, two Class III directors were elected to serve until the 2027 annual meeting. The elected directors are Blake Borgeson, Ph.D., with 165,914,956 votes for and 26,093,759 withheld, and Dean Y. Li, M.D., Ph.D., with 166,211,058 votes for and 25,797,657 withheld. Additionally, an advisory resolution to approve executive compensation was passed with 188,317,831 votes for, 2,887,180 against, and 803,704 abstentions. The details of these proposals and their descriptions were previously filed with the SEC in the definitive Proxy Statement on April 23, 2024. The annual meeting's outcomes were reported in compliance with the SEC regulations.
Recursion Pharmaceuticals公司于2024年6月3日举行了2024年股东大会。在会议期间,两位三类董事会成员当选,并将服务于2027年股东大会。当选的董事是Blake Borgeson博士,获得了165,914,956票赞成和26,093,759票弃权,以及Dean Y. Li医学博士,获得了166,211,058票赞成和25,797,657票弃权。此外,一项关于批准高管薪酬的咨询性决议获得了188,317,831票赞成,2,887,180票反对和803,704票弃权。这些提案及其描述的详细信息已于2024年4月23日在提交给SEC的正式代理声明中进行了披露。本次年度股东大会的结果符合SEC监管规定。
Recursion Pharmaceuticals公司于2024年6月3日举行了2024年股东大会。在会议期间,两位三类董事会成员当选,并将服务于2027年股东大会。当选的董事是Blake Borgeson博士,获得了165,914,956票赞成和26,093,759票弃权,以及Dean Y. Li医学博士,获得了166,211,058票赞成和25,797,657票弃权。此外,一项关于批准高管薪酬的咨询性决议获得了188,317,831票赞成,2,887,180票反对和803,704票弃权。这些提案及其描述的详细信息已于2024年4月23日在提交给SEC的正式代理声明中进行了披露。本次年度股东大会的结果符合SEC监管规定。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息